Startups
PureTech Health
Boston, Massachusetts, United States · London, United Kingdom
PureTech Health is a Boston-based biotherapeutics and company-creation business operating through UK public parent PureTech Health plc and its wholly owned Delaware subsidiary PureTech Health LLC. The SEC history identifies predecessor operations and an initial financing greater than USD5M in2004; the plc was incorporated May8,2015 and acquired its predecessor in the June2015 IPO reorganization. It develops therapeutic programs and forms separately financed Founded Entities, retaining equity, royalties and contractual milestone rights. Relevant neuroscience programs include cognitive digital therapeutics at Akili, Karuna’s muscarinic schizophrenia treatment Cobenfy and Seaport’s Glyph platform for neuropsychiatric medicines. Its broader research spans drug delivery, immunology, fibrosis and oncology. The published sources support neuroscience and biotechnology relevance; they do not establish PureTech as a generative-AI model company. Its current public roster identifies CEO Robert Lyne, appointed permanently December18,2025; earlier Daphne Zohar/Bharatt Chowrira CEO roles are historical. Scientific collaborators are external academic/industry affiliations rather than an employee list. PureTech maintains its primary London Stock Exchange listing; in April2026 it announced voluntary Nasdaq ADS delisting and a planned transition to an OTC ADR program, with execution details source-qualified rather than assuming continued Nasdaq listing. SEC2025 financial statements document actual parent IPO gross proceedsUSD171M plus25M over-allotment in2015, and approximately100M gross placing in2018. Parent cash balances, amounts raised by Founded Entities, royalty monetization proceeds, acquisition exits and contingent licensing milestones are not new parent equity financings or LP-fund closes. This is a corporate issuer and venture creator, not a standalone private VC fund. Akili2016 financing was received in tranches; parent annuals confirm42.4M total actualAkili financings thatyear with25M fromPureTech, distinct from PureTech’s own capital raises.
Founded 2004
Team
 Allison Mead TalbotSenior Vice President, Communications |
Bill BradfordScientific Collaborator (external; published network) |
 Charles SherwoodChief Operating Officer and General Counsel |
Christopher PorterScientific Collaborator (external; published network) |
 Daphne ZoharFounder |
 Eric ElenkoCo-Founder (published acting CEO of Gallop Oncology) |
 H. Robert HorvitzBoard Observer and R&D Committee Chair · Scientific Collaborator (external; published network) |
 John LaMattinaIndependent Non-Executive Director |
Kevin FlahertyScientific Collaborator (external; published network) |
 Kiran Mazumdar-ShawIndependent Non-Executive Director |
Marlies WijsenbeekScientific Collaborator (external; published network) |
Maryanne SennaScientific Collaborator (external; published network) |
 Maurizio FavaScientific Collaborator (external; published network) |
Michael A. RogawskiScientific Collaborator (external; published network) |
 Michael InbarChief Accounting Officer |
 Michele HolcombIndependent Non-Executive Director and Audit Committee Member |
 Murray SteinScientific Collaborator (external; published network) |
Paul NobleScientific Collaborator (external; published network) |
 Robert LangerCo-Founder and Non-Executive Director |
 Robert LyneChief Executive Officer · Board Director |
Samantha Meltzer-BrodyScientific Collaborator (external; published network) |
 Sharon Barber-LuiInterim Chair of the Board and Audit Committee Member |
 Stephen BrannanScientific Collaborator (external; published network) |
 Steven PaulScientific Collaborator (external; published network) |
Toby MaherScientific Collaborator (external; published network) |
Vincent CottinScientific Collaborator (external; published network) |
Investments
| $225M2024-10-21 |  Seaport Therapeutics | ARCH Venture Partners, T. Rowe Price, General Atlantic, Canada Pension Plan Investment Board, Sofinnova Partners, Third Rock Ventures, PureTech Health |
| $162M2022-08-19 |  Akili Interactive | Social Capital, Polaris Partners, EvidityHealthCapital, JAZZ Venture Partners, Amgen Ventures, Temasek, Omidyar Technology Ventures, PureTech Health, Alyeska Investment Group, Apeiron Investment Group, Montanova Capital |
| $100M2018-03-12 | PureTech Health | 0 participations |
| $30M2016-01-22 | Akili Interactive | JAZZ Venture Partners, EvidityHealthCapital, PureTech Health |
| $25M2015-07-02 | PureTech Health | 0 participations |
| $171M2015-06-24 | PureTech Health | 0 participations |
| $52M2015-01-09 | PureTech Health | 0 participations |
| $—Unknown date |  Vor Biopharma | PureTech Health |
| $—Unknown date |  Karuna Therapeutics | PureTech Health |
| $—Unknown date | PureTech Health | 0 participations |